SMARCA4-mutant lung cancer is one of the worst prognosis subtypes of lung cancer with dismal outcome and poor response to chemotherapy, immunotherapy and even recently approved KRASG12C inhibitors 70–74. The gene discussed is SMARCA4; the disease is lung carcinoma.